Episode Details

ACN (Accenture) reported Q3 FY2026 earnings on 2026-06-18. Stock fell 5.7% on the print. Here's the breakdown: Is ACN a buy, hold, or sell after this quarter? In this Accenture (ACN) Q3 FY2026 earnings breakdown we cover the revenue and EPS print, the 8-quarter trend, segment detail, the free-cash-flow bridge, forward guidance, peer valuation, and management & earnings quality - ending with a clear price-aware Buy / Hold / Avoid Call and a Wall Street consensus comparison. If you follow Technology stocks or ACN earnings, this is the Q3 FY2026 deep dive. 🎧 Listen on Podbean: https://chargedalpha.podbean.com (also on Apple Podcasts & Spotify) 🔔 Subscribe for daily earnings deep-dives → @ChargedAlpha | Call tracker: chargedalpha.com THE CALL: BUY (3/5 conviction, MODERATE) - CURRENT @ $156.01 - BUY - BUY below $150.00 with $128.00 stop - AVOID above $210.00 TRIGGER: Two consecutive quarters of POSITIVE new-bookings growth / book-to-bill back above 1.1x WINDOW: Through Q4 FY26 earnings (late September 2026) and the first FY27 guide TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 0 Strong Buy / 37 Buy / 15 Hold / 1 Sell / 0 Strong Sell - BUY - Median 12-month price target: $215.00 (range $160 - $290) - Charged Alpha vs consensus: IN LINE THESIS The scale leader in IT services + consulting, margin-expanding and throwing off ~$11B/yr of free cash flow, priced at a decade-low ~12x because the market fears generative AI will eat consulting. Bull lever: If new bookings re-accelerate over the next 1-2 quarters and AI work proves additive, the multiple re-rates off the 12x trough toward the $221 target while $9.5B/yr of capital return pays you to wait. Key risk: Bookings already turned negative; if book-to-bill keeps slipping, the AI-cannibalization fear is validated, EPS guidance follows down, and 12x proves cheap-for-a-reason rather than a gift. QUALITY CHECK - Management quality grade: A- (CEO Julie Sweet runs a disciplined, high-return operation - operating margin expanded even as growth slowed, capital return is robust (~$9.) - Earnings quality grade: A- (High quality: GAAP earnings backed by $3.6B of real free cash flow (~19% margin), no adjusted-vs-GAAP gap to speak of, and a buyback that's genuinely shrinking the share count.) CHAPTERS 0:00 Hook 0:12 The Year in One Chart 0:51 The Print 1:27 Beat Decomposition 2:01 The Trend 2:39 The Segments 3:19 The FCF Bridge 3:56 Margin Quality 4:33 Guidance & The Narrative Diff 5:22 Catalyst Calendar 6:00 Peer Dot-Plot 6:37 Valuation 7:14 Management & Earnings Quality 7:56 The Call - Verdict 8:36 The Call - Evidence 9:15 The Call - Supporting Figures KEY METRICS - Q3 FY2026 - Revenue: $18.72B (YoY +6.0%, beat est by +0.9%) - EPS: $3.80 (vs $3.71 est, beat +2.4%) - Operating margin: 17.0% - Free cash flow: $3.60B (19.2% margin) ACN Q3 FY2026: an EPS beat that fell 5.7% to a 52-week low. Diluted EPS $3.80 +9% beat $3.71; rev $18.72B +6% USD/+3% LC; op margin 17.0% +20bps; FCF $3.6B. BUT new bookings FELL 2% to $19.3B, consulting near-stalled +1% LC, FY26 revenue top-end cut on a US-federal drag. Stock now ~12x fwd (decade low, from 30x), +42% to the $221 avg target, Buy Street. BUY conv 3 (discount vs declining bookings). CEO Julie Sweet. The AI-eats-consulting debate. NARRATIVE DIFF - what changed in management tone - Prior call: "We see strong demand for enterprise-scale generative AI and remain confident in our reinvention strategy for fiscal 2026." - This call: "Enterprise-scale AI is not something a chatbot can do; it requires the kind of reinvention work we do every day for the world's leading companies." - Tone shift: The beat didn't matter because the bookings - the leading indicator - confirmed the deceleration the bears feared. A stock already pricing structural AI impairment fell another 5.7% to a decade-low ~12x. The operating data still says quality compounder; the orders say prove-it-first. That gap is the whole debate.